General Announcement::The US FDA Approves First Supplemental Abbreviated New Drug Application

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
19-Jun-2018 12:26:20
Status
New
Announcement Sub Title
The US FDA Approves First Supplemental Abbreviated New Drug Application
Announcement Reference
SG180619OTHRL4AP
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
19/06/2018 10:00:00
Description (Please provide a detailed description of the event in the box below)
Sub: The US FDA Approves First Supplemental Abbreviated New Drug Application (sANDA) for Glenmark Pharmaceuticals Manufacturing Facility in Monroe, North Carolina

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Request you to kindly take the same on record.

Attachments

PR_19062018.pdf
Total size =3296K